TY - CHAP M1 - Book, Section TI - Multiple Myeloma and Other Plasma Cell Disorders A1 - Braggio, Esteban A1 - Fonseca, Rafael A2 - Murray, Michael F. A2 - Babyatsky, Mark W. A2 - Giovanni, Monica A. A2 - Alkuraya, Fowzan S. A2 - Stewart, Douglas R. PY - 2014 T2 - Clinical Genomics: Practical Applications in Adult Patient Care AB - Disease summary:Multiple myeloma (MM) is a plasma cell malignancy characterized by accumulation of clonal antibody-secreting plasma cells.MM accounts for 1% of all cancers and 10% of all hematologic malignancies.Almost all MM evolves from an asymptomatic premalignant stage termed as monoclonal gammopathy of undetermined significance (MGUS).MM is now believed to be curable in only a small fraction of cases, and has a median overall survival of 5 years.The major clinical manifestations are bone lesions, anemia, hypercalcemia, renal failure, and an increased risk of infections.Genetic abnormalities are used for disease risk stratification and therapeutic decision making. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1102700116 ER -